Book context
What does NAD+ vs MOTS-c explain?
This book compares two distinct subjects in longevity research. NAD+ is a cellular coenzyme involved in redox reactions and energy metabolism, not a peptide; MOTS-c is a mitochondrial-derived peptide studied as a signaling molecule. It reviews proposed mechanisms, human evidence where available, biomarker interpretation, sourcing, and uncertainty without turning either subject into a dose, treatment, or efficacy recommendation.
Written by Mark Holshouser · An educational, evidence-weighted comparison of NAD+ and MOTS-c research, including mechanisms, human evidence, biomarker interpretation, and sourcing considerations.
Primary topics
- →NAD+ and MOTS-c mechanisms
- →Human clinical evidence
- →Biomarker tracking
- →Sourcing and quality control
Intended reader
Readers who want a focused, evidence-weighted comparison of NAD+ and MOTS-c research and its stated limitations.
Frequently asked questions
What is the difference between NAD+ and MOTS-c?
NAD+ is a small coenzyme found in cells, where it participates in redox reactions and energy metabolism. MOTS-c is a short mitochondrial-derived peptide encoded within mitochondrial 12S rRNA and studied as a signaling molecule. Their chemistry, origin, and proposed roles differ, so the book compares them without treating them as interchangeable products or equivalent interventions.
What human evidence does the book discuss?
The book separates human evidence from animal, cell, and mechanistic findings. For NAD+, it discusses relevant human research on NAD+ biology and related interventions; for MOTS-c, it identifies where evidence is limited or primarily preclinical. It also explains why a change in a biomarker does not by itself establish a meaningful clinical outcome or prove effectiveness.
Who is this comparison for?
This comparison is for readers who want a clear introduction to NAD+ and MOTS-c research, including definitions, proposed mechanisms, study types, and evidence limits. It may help readers read longevity claims more carefully, but it is not a personal plan, medical assessment, or recommendation to use either substance. Questions about individual health belong with a qualified clinician.
Inside This Book
NAD+ as a cellular coenzyme vs MOTS-c as a mitochondrial-derived peptide signal
What the human clinical evidence actually shows for each compound
How to interpret biomarker research without treating it as a clinical outcome
How a 90-day foundation framework is discussed, including what tracking can—and cannot—show
Sourcing, quality control, and red flags in the supplement market
26 peer-reviewed citations from Cell, Science, Nature, and others
"Evidence, context, and room for uncertainty."